Previous close | 6.05 |
Open | 5.89 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 5.89 - 6.44 |
52-week range | 3.69 - 44.56 |
Volume | |
Avg. volume | 442,632 |
Market cap | 8.452M |
Beta (5Y monthly) | 1.93 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 25 Mar 2024 |
1y target est | N/A |
TAMPA, FL, April 23, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH, Inc. (Nasdaq: MEDS) (the “Company”), announced that, on April 17, 2024, the Company received a notice (the “Notice”) from the Nasdaq Listing Qualifications Department (“Nasdaq”) indicating that because the Company had not yet filed its Annual Report on Form 10-K for the 2023 fiscal year (the “Form 10-K”), the Company was not compliant with the timely filing requirement for continued listing under Nasdaq Listing Rule 5250(c)(1) (the “Li
TAMPA, FL, March 06, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH Inc. (Nasdaq: MEDS) (the “Company”), announced that the Company’s board of directors has declared a special cash dividend of $8.00 per share of common stock. The special dividend is being paid using a portion of the proceeds from the closing of the recently announced sale of the Company’s web-based market platform assets. The special cash dividend is payable to stockholders of record as of March 18, 2024, with the dividend being paid on
TAMPA, FL, Jan. 17, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH, INC. (NASDAQ: MEDS) (“TRxADE”), a parent company of pharmaceutical business-to-business exchange platform, announced today that it filed its Quarterly Report on Form 10-Q for the period ended September 30, 2023 (the “Form 10-Q”). On November 21, 2023, the Company received a standard notice of noncompliance from the Nasdaq Listing Qualifications Department (“Nasdaq”) indicating that, as a result of not having timely filed its Form 10-Q,